Roche Holding AG (ROG.VX) Wednesday said new data shows its experimental medicine pertuzumab is effective in treating breast cancer, providing a welcome boost for the Swiss drug giant after its key oncology product Avastin lost its U.S. breast cancer label earlier this month.
The detailed research, which will be presented at this year's Breast Cancer Symposium in San Antonio that starts December 6, includes results from a late-stage study of pertuzumab used in combination with Roche's cancer medicine Herceptin and chemotherapy docetaxel.
"The data shows that pertuzumab is effective and we plan to file the drug for health authority review this year," Stefan Frings, Head Medical Affairs Oncology at Roche, told Dow Jones Newswires. Roche will file the drug, which works by blocking cancer-causing protein HER2, as a first line treatment in HER2-positive metastatic breast cancer.
"Given the strong data, we also have started a full phase III trial in the adjuvant setting," he said. In medical trials, the term adjuvant refers to treatments that are undertaken after surgery.
The potential approval of pertuzumab should help Roche protect its strong cancer franchise. The growth potential of Roche's core business was questioned after U.S. regulators in November revoked the breast cancer label for Avastin, Roche's best-selling cancer drug besides Herceptin and Rituxan.
Some analysts also expect pertuzumab to help Roche alleviate generic pressure once Herceptin loses its patent. "The market is materially undervaluing pertuzumab in HER2 breast cancer, which will help negate the potential negative impact of Herceptin biosimilars," said Citigroup analyst Andrew Baum.
Investors widely shunned Roche stock during 2010 due to several development setbacks. But Roche's shares pushed higher Wednesday and at 1203 GMT stood 0.9% higher at CHF142.9 in an unchanged overall market.
Roche has so far only said that late stage data has shown that pertuzumab, in combination with other treatments, helped some breast cancer patients live "significantly" longer without their disease worsening. Because of the dearth of detailed data, some analysts remain skeptical about the drug's chances to win approval. But some, like Bank Vontobel, expect the medicine to reach sales of close to $2 billion.
Another issue for analysts is the quality of the data, as Roche is using progression-free survival, or PFS, data to highlight the drug's effectiveness. Unlike overall survival rate, which denotes a percentage of patients who still live after taking a drug within a pre-defined period, PFS is the length of time during and after medication when the disease being treated doesn't get worse. Regulators have become wary of PFS, especially for first-line treatments.
"Progression free survival is a meaningful primary endpoint and a direct measure of the drug's effect," said Roche's Frings. "The data is quicker to measure, the drugs can potentially reach patients faster, and the outcome is not confounded by subsequent treatment lines," he said.
-By Goran Mijuk, Dow Jones Newswires, +41 43 443 80 47; goran.mijuk@dowjones.com
Recent RHHBY News
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Roche's Cancer Injection Tecentriq SC Gets European Commission Approval • Dow Jones News • 01/16/2024 06:49:00 AM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche • Dow Jones News • 12/29/2023 10:07:00 PM
- Roche's Xolair Granted FDA Priority Review • Dow Jones News • 12/19/2023 03:27:00 PM
- Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment • Dow Jones News • 12/11/2023 03:31:00 PM
- Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment • Dow Jones News • 12/08/2023 05:56:00 PM
- Roche's Inavolisib Breast Cancer Drug Gets Positive Results • Dow Jones News • 12/08/2023 05:38:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study • Dow Jones News • 12/05/2023 06:54:00 AM
- Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion • Dow Jones News • 12/04/2023 03:12:00 PM
- Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update • Dow Jones News • 12/04/2023 11:34:00 AM
- Alaska Air Acquires Hawaiian Holdings, Spotify Cuts 1,500 Jobs, Uber’s S&P 500 Entry, and More • IH Market News • 12/04/2023 10:55:07 AM
- Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Billion • Dow Jones News • 12/04/2023 06:47:00 AM
- Roche's Genentech, Nvidia Team Up to Accelerate Drug Discovery With AI • Dow Jones News • 11/21/2023 04:06:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2023 10:14:35 PM
- Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal • Dow Jones News • 10/31/2023 06:26:00 AM
- Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment • Dow Jones News • 10/27/2023 05:40:00 AM
- Trending: Roche to Buy Telavant From Roivant and Pfizer • Dow Jones News • 10/23/2023 07:41:00 PM
- Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update • Dow Jones News • 10/23/2023 08:16:00 AM
- Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal • Dow Jones News • 10/23/2023 05:50:00 AM
- Roche Shares Fall on Lower Sales Due to Currency Hit • Dow Jones News • 10/19/2023 09:55:00 AM
- Roche Backs Guidance After Sales Fall • Dow Jones News • 10/19/2023 05:48:00 AM
- Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial • Dow Jones News • 10/18/2023 06:14:00 AM
- Roche's Elecsys IL-6 Test Approved for Diagnosis of Neonatal Sepsis • Dow Jones News • 10/18/2023 05:54:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM